Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Legislation

Set Alert for Legislation

Latest From Legislation

India Government Procurement Preference Norms – Rising Local Flavour

Increasing local content requirements have been stipulated in the public purchase preference norms for medicines in India. Backward-integrated Indian firms stand to gain but progressive localization requirements for drugs not made in India appear to be a tough ask.
India Policy

Pharmacists To Get New Substitution Powers To Tackle Brexit Shortage Risk

In an effort to address possible serious drug shortages in the event of a no-deal Brexit, the UK government has formally proposed giving pharmacists wide powers to dispense alternative medicines such as different forms, generics, biosimilars, or “therapeutically equivalent” drugs.
Brexit United Kingdom

Trump’s Big Missed Opportunity: Medicare For All

With control over all branches of government, President Trump and Republicans made a choice to pursue repeal of the ACA and tax cuts over a strategy that could have redefined the party: Medicare For All with competitive private sector principles. 
Pricing Debate Legislation

PhRMA Adds Genentech, Gilead To Its Ranks Ahead Of House Democrats’ Drug Pricing Scrutiny

Roche, through Genentech, returns to the PhRMA fold after leaving the trade group in 2009; Gilead is a first-time member; both are retaining their BIO memberships as well.

Pricing Debate Research and Development Strategies

European Council Move Brings SPC Manufacturing Waiver A Step Closer

A proposed SPC manufacturing waiver – which would allow generic and biosimilar manufacturing within Europe during the SPC period – has taken a step closer to being realized after the European Council approved a mandate for negotiations with the European Parliament. However, it remains uncertain whether key elements desired by the off-patent industry will fall into place.

Europe Manufacturing

Bristol-Celgene: Congressional Reps Want Assurance Merger Will Not Increase Prices

Reps. Welch and Rooney urge FTC and DOJ to condition their approval of the merger on inclusion of a pricing provision.

Pricing Debate M & A
See All
UsernamePublicRestriction

Register